Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.

Giżewska M, Inwood A, Tyčová R, Vijay S, Fjellbirkeland O, van Spronsen F, Venegas-Moreno EM, Guilder L, Burlina A, Peters H, Potter M, Grošelj U, Chakrapani A, Bélanger-Quintana A, Maillot F, Rutsch F, Arnoux JB, Tchan M, Ingalls K, Zhao Z, Hughes C, Smith N, Muntau AC

Open source

DOI: 10.1016/j.metabol.2026.156513
Published: 2026 May
Container: Metabolism: clinical and experimental
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.metabol.2026.156513,
  title = {Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.},
  author = {Giżewska M and Inwood A and Tyčová R and Vijay S and Fjellbirkeland O and van Spronsen F and Venegas-Moreno EM and Guilder L and Burlina A and Peters H and Potter M and Grošelj U and Chakrapani A and Bélanger-Quintana A and Maillot F and Rutsch F and Arnoux JB and Tchan M and Ingalls K and Zhao Z and Hughes C and Smith N and Muntau AC},
  year = {2026},
  journal = {Metabolism: clinical and experimental},
  doi = {10.1016/j.metabol.2026.156513},
  url = {https://doi.org/10.1016/j.metabol.2026.156513}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.
AU  - Giżewska M
AU  - Inwood A
AU  - Tyčová R
AU  - Vijay S
AU  - Fjellbirkeland O
AU  - van Spronsen F
AU  - Venegas-Moreno EM
AU  - Guilder L
AU  - Burlina A
AU  - Peters H
AU  - Potter M
AU  - Grošelj U
AU  - Chakrapani A
AU  - Bélanger-Quintana A
AU  - Maillot F
AU  - Rutsch F
AU  - Arnoux JB
AU  - Tchan M
AU  - Ingalls K
AU  - Zhao Z
AU  - Hughes C
AU  - Smith N
AU  - Muntau AC
PY  - 2026
JO  - Metabolism: clinical and experimental
DO  - 10.1016/j.metabol.2026.156513
UR  - https://doi.org/10.1016/j.metabol.2026.156513
ER  -

APA

M, G., A, I., R, T., S, V., O, F., F, V. S., EM, V., L, G., A, B., H, P., M, P., U, G., A, C., A, B., F, M., F, R., JB, A., M, T., K, I., Z, Z., C, H., N, S., & AC, M. (2026). Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.. Metabolism: clinical and experimental. https://doi.org/10.1016/j.metabol.2026.156513

Source records

pubmed · retrieved 2026-09-26T12:12:02.084Z